Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
收藏NIAID Data Ecosystem2026-03-14 收录
官方服务：
资源简介：
This is a Phase 1/2, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1133 in patients with advanced solid tumor malignancy harboring a KRAS G12D mutation.
创建时间：
2023-03-15
